These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 36198840)

  • 21. Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial.
    Fiuzat M; Ezekowitz J; Alemayehu W; Westerhout CM; Sbolli M; Cani D; Whellan DJ; Ahmad T; Adams K; Piña IL; Patel CB; Anstrom KJ; Cooper LS; Mark D; Leifer ES; Felker GM; Januzzi JL; O'Connor CM
    JAMA Cardiol; 2020 Jul; 5(7):757-764. PubMed ID: 32319999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF.
    Jering KS; Zannad F; Claggett B; Mc Causland FR; Ferreira JP; Desai A; Barkoudah E; McMurray JJV; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2021 Jan; 9(1):13-24. PubMed ID: 33189633
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction.
    Givertz MM; Stevenson LW; Costanzo MR; Bourge RC; Bauman JG; Ginn G; Abraham WT;
    J Am Coll Cardiol; 2017 Oct; 70(15):1875-1886. PubMed ID: 28982501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
    Turgeon RD; Kolber MR; Loewen P; Ellis U; McCormack JP
    PLoS One; 2019; 14(2):e0212907. PubMed ID: 30817783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure.
    Ji PJ; Zhang ZY; Yan Q; Cao HL; Zhao YJ; Yang B; Li J
    ESC Heart Fail; 2023 Apr; 10(2):1314-1325. PubMed ID: 36722326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mortality and guideline-directed medical therapy in real-world heart failure patients with reduced ejection fraction.
    McCullough PA; Mehta HS; Barker CM; Van Houten J; Mollenkopf S; Gunnarsson C; Ryan M; Cork DP
    Clin Cardiol; 2021 Sep; 44(9):1192-1198. PubMed ID: 34342033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER.
    Wang X; Vaduganathan M; Claggett BL; Hegde SM; Pabon M; Kulac IJ; Vardeny O; O'Meara E; Zieroth S; Katova T; McGrath MM; Pouleur AC; Jhund PS; Desai AS; Inzucchi SE; Kosiborod MN; de Boer RA; Kober L; Sabatine MS; Martinez FA; Ponikowski P; Shah SJ; Hernandez AF; Langkilde AM; McMurray JJV; Solomon SD; Lam CSP
    Circulation; 2023 Feb; 147(8):624-634. PubMed ID: 36342789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials.
    Wang R; Ye H; Zhao Y; Wei J; Wang Y; Zhang X; Wang L
    BMC Med; 2022 Dec; 20(1):487. PubMed ID: 36527023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in provider approach to initiating and titrating guideline directed medical therapy in heart failure with reduced ejection fraction.
    Cordwin DJ; Guidi J; Alhashimi L; Hummel SL; Koelling TM; Dorsch MP
    BMC Cardiovasc Disord; 2024 May; 24(1):247. PubMed ID: 38730379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.
    Greene SJ; Butler J; Albert NM; DeVore AD; Sharma PP; Duffy CI; Hill CL; McCague K; Mi X; Patterson JH; Spertus JA; Thomas L; Williams FB; Hernandez AF; Fonarow GC
    J Am Coll Cardiol; 2018 Jul; 72(4):351-366. PubMed ID: 30025570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials.
    Rossello X; Ferreira JP; Pocock SJ; McMurray JJV; Solomon SD; Lam CSP; Girerd N; Pitt B; Rossignol P; Zannad F
    Eur J Heart Fail; 2020 May; 22(5):834-844. PubMed ID: 32077220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between visit frequency, continuity of care, and pharmacy fill adherence in heart failure patients.
    Hamo CE; Mukhopadhyay A; Li X; Zheng Y; Kronish IM; Chunara R; Dodson J; Adhikari S; Blecker S
    Am Heart J; 2024 Jul; 273():53-60. PubMed ID: 38621576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sacubitril/valsartan vs. angiotensin receptor inhibition in heart failure: a real-world study in Taiwan.
    Chang PC; Wang CL; Hsiao FC; Wen MS; Huang CY; Chou CC; Chu PH
    ESC Heart Fail; 2020 Oct; 7(5):3003-3012. PubMed ID: 32720478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
    Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.
    Bouabdallaoui N; O'Meara E; Bernier V; Komajda M; Swedberg K; Tavazzi L; Borer JS; Bohm M; Ford I; Tardif JC
    ESC Heart Fail; 2019 Dec; 6(6):1199-1207. PubMed ID: 31591826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice: A Cluster Randomized Trial.
    Ghazi L; Yamamoto Y; Riello RJ; Coronel-Moreno C; Martin M; O'Connor KD; Simonov M; Huang J; Olufade T; McDermott J; Dhar R; Inzucchi SE; Velazquez EJ; Wilson FP; Desai NR; Ahmad T
    J Am Coll Cardiol; 2022 Jun; 79(22):2203-2213. PubMed ID: 35385798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis.
    Ameri P; De Marzo V; Zoccai GB; Tricarico L; Correale M; Brunetti ND; Canepa M; De Ferrari GM; Castagno D; Porto I
    Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 8(8):768-776. PubMed ID: 34928347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan.
    Yang M; Butt JH; Kondo T; Jering KS; Docherty KF; Jhund PS; de Boer RA; Claggett BL; Desai AS; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Langkilde AM; Martinez FA; Petersson M; Shah SJ; Vaduganathan M; Wilderäng U; Solomon SD; McMurray JJV
    Eur J Heart Fail; 2022 Dec; 24(12):2307-2319. PubMed ID: 36342375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.